No Data
No Data
No Data
No Data
No Data
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients With Mutated NSCLC
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to
GlobeNewswireApr 16 04:15
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
TipRanksApr 9 19:40
ORIC Pharmaceuticals Presents Preclinical Data On Two Programs At The 2024 AACR Annual Meeting
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors.
BenzingaApr 8 20:15
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
GlobeNewswireApr 6 04:30
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
GlobeNewswireApr 5 04:30
Oric Pharmaceuticals Bolsters Incentive Plan to Attract Talent
TipRanksMar 30 04:33
No Data
No Data